HKG Movements | Laekna Medicine-B (LAE002) surged over 5% in the morning session as Phase III clinical trials reached their endpoint; an application for market listing is expected to be submitted.

Laikang Medicine-B (02105) surged over 5% in the morning session. As of the time of writing, it was up 5.14%, trading at HKD 14.32 with a turnover of HKD 13.0107 million.

Zhitong FinanceMay 13 23:58 ET

MSCI Global Small Cap Index May Adjustment: Meitu (01357) and 13 other stocks included, while Jianpu Technology (06166) and 20 others removed.

On May 13, MSCI (Ming Sheng Company), an international index compiler, announced the results of its quarterly index adjustment for May 2026. This adjustment will take effect after the market close on May 29.

Zhitong FinanceMay 12 22:01 ET

Laekna Sees Insider Stock Selling

Simply Wall StMay 12 02:40 ET

H-share Movement | Laekna Medicine-B (02105) surged over 10% in the afternoon session as Qilu Pharmaceutical advances the marketing application for LAE002. The company is expected to receive an upfront payment and milestone-based payments.

Laikai Medicine-B (02105) surged over 10% in the afternoon session. As of the time of writing, it was up 9.63%, trading at HKD 14.8, with a turnover of HKD 60.8913 million.

Zhitong FinanceMay 11 02:32 ET

Laikai Medicine-B (02105) issued a total of 2,865,000 shares to meet the vesting requirements of RSUs granted under the 2024 Share Incentive Plan.

Laikai Pharmaceuticals-B (02105) announced that on May 8, 2026, the company issued a total of 2,865,000 ordinary shares to meet the vesting requirements of RSUs granted under the 2024 Share Award Plan.

Zhitong FinanceMay 10 20:06 ET

Bank of America Securities Reaffirms Their Buy Rating on Laekna, Inc. (2105)

TipRanksMay 7 20:27 ET · Ratings